期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer 被引量：1

Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer
下载PDF
导出
摘要 Combination immunotherapy is emerging as a promising approach for the treatment of advanced prostate cancer. This research highlight discusses the combination of a PSA-directed pox-viral vaccine and a monoclonal antibody blocking an important immune checkpoint molecule to treat men with metastatic castration- resistant prostate cancer. The results demonstrate feasibility and safety, as well as intriguing clinical responses to this combination therapy. Combination immunotherapy is emerging as a promising approach for the treatment of advanced prostate cancer. This research highlight discusses the combination of a PSA-directed pox-viral vaccine and a monoclonal antibody blocking an important immune checkpoint molecule to treat men with metastatic castration- resistant prostate cancer. The results demonstrate feasibility and safety, as well as intriguing clinical responses to this combination therapy.
作者 Emmanuel S Antonarakis
机构地区 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2012年第4期520-521,共2页 亚洲男性学杂志（英文版）
分类号 S852.4 [农业科学—基础兽医学] Q78 [生物学—分子生物学]
  • 相关文献

参考文献9

  • 1Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ et al. SipuleuceI-T immunotherapy for castration- resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
  • 2Hodi FS, O'Day S J, McDermott DF, Weber RW, Sosman JA et al. Improved survival with ipifimumabin patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
  • 3RobeE C, Thomas L, Bondarenko I, O'Day S, Weber J et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517 26.
  • 4Madan RA, Mohebtash M, Aden PM, Vergati M, Rauckhorst Met al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 501-8.
  • 5Kantoff PW, Schuetz T J, Blumenstein BA, GIode LM Bilhartz DL etal. Overall survival analysis of a phase I randomized controlled trial of a Poxviral-based PSA targeted immunotherapy in metastatic castration resistant prostate cancer. J Clin Oncol 2010; 28 1099-105.
  • 6Small E J, Tchekmedyian NS, Rini BI, Fong L, Lowy I etal. A pilot trial of CTLA-4 blockade with human anti- CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 1810-5.
  • 7van den Eertwegh A J, Versluis J, van den Berg HP, Santegoets S J, van Moorselaar RJ et aL Combined immunotherapy with gra nu Iocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Onco12012; 13: 509-17.
  • 8Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167 75.
  • 9Antonarakis ES, Drake CG. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin 0ncol2012; 24: 258-65.

引证文献1

二级引证文献21

Asian Journal of Andrology
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部